arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Lantheus Holdings, Inc.

LNTH
$99.99 ▼ -0.05 (-0.04%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
52 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
85
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Lantheus Holdings, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $6.5B
Dividend Yield —
Revenue Growth 2.7% ↗
Op. Margin 25.8% ↗
ROIC 6.1% ↗
FCF / Share $1.42 ↘
Trailing P/E 87.0x
Price / Book 5.0x
FCF Yield 1.4%
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

52-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$388.18M
↑ +2.7% —
Net Income Profit after all expenses
$118.42M
↑ +62.3% —
Operating Margin Operating profit as % of sales
25.8%
↑ +19.8% 75th
FCF / Share Free cash flow per share
$1.42
↓ -26.8% —
Long-Term Debt Long-term obligations
$181.72M
↓ -18.4% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
80
Returns
88
Financial Health
89
Cash Quality
82

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 14 years · 52 quarters